U.S. IRS imposes $32,350 penalty on Dr. Reddy’s arm
The U.S. IRS has fined a subsidiary of Dr. Reddy’s Laboratories $32,350 due to a fiscal year reference misclassification. The parent company stated that the penalty will have no material impact on its financial operations.
Why it matters
It serves as a reminder of the regulatory compliance requirements for multinational corporations operating in the U.S. market.
A step-down wholly owned U.S. subsidiary of pharma major Dr. Reddy’s Laboratories has been levied a $32,350.20 penalty by the U.S. Internal Revenue Service (IRS).
The penalty on Dr. Reddy’s Laboratories Inc., the subsidiary, is due to misclassification of fiscal year reference at the time of tax payment, the Hyderabad-based parent company said citing the order from the Department of Treasury, Internal Revenue Service, Cincinnati. The company received the final transcript dated September 25, 2026, from the Department, on October 2, 2026 classifying an amount $32,350.20 as a penalty levied by IRS.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in